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Abstract: We aimed to examine the complex relationships between patient safety processes and
outcomes and multimorbidity using a comprehensive set of constructs: multimorbidity, polyphar-
macy, discordant comorbidity (diseases not sharing either pathogenesis nor management), morbidity
burden and patient complexity. We used cross-sectional data from 4782 patients in 69 primary care
centres in Spain. We constructed generalized structural equation models to examine the associations
between multimorbidity constructs and patient-reported patient safety (PREOS-PC questionnaire).
These associations were modelled through direct and indirect (mediated by increased interactions
with healthcare) pathways. For women, a consistent association between higher levels of the multi-
morbidity constructs and lower levels of patient safety was observed via either pathway. The findings
for men replicated these observations for polypharmacy, morbidity burden and patient complexity via
indirect pathways. However, direct pathways showed unexpected associations between higher levels
of multimorbidity and better safety. The consistent association between multimorbidity constructs
and worse patient safety among women makes it advisable to target this group for the development
of interventions, with particular attention to the role of comorbidity discordance. Further research,
particularly qualitative research, is needed for clarifying the complex associations among men.
Keywords: multimorbidity; polypharmacy; patient safety; primary care; structural equation model;
latent class analysis
1. Introduction
The safety of primary care is a global priority for healthcare, led by the World Health
Organization [1]. Patient safety is defined as “the avoidance, prevention and amelioration
of adverse outcomes or injuries stemming from the process of healthcare” [2], and the
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harm arising from a patient safety incident as “impairment of structure or function of the
body and/or any deleterious effect arising there from, including disease, injury, suffering,
disability and death, and may be physical, social or psychological” [1]. Around 2% to 3% of
all primary care encounters result in a patient safety incident, with 1 in 25 causing a serious
harm outcomes [3]. These incidents are frequently related to diagnosis (either delayed or
missed) or to treatment (delayed or inappropriate) [4,5]. A number of different factors
contribute to these incidents, such as the working environment, information transfer at the
primary–secondary interface, doctor–patient relationship or continuing education [6–8].
Multimorbidity, the presence of more than one health condition in an individual [9], is
increasingly prevalent and represents a major part of the workload of primary care [10,11].
Although the prevalence increases substantially with age, in absolute terms, multimor-
bidity is more prevalent in those aged 65 years or less and is much more common in
socioeconomically deprived areas, so that they develop equivalent levels of multimorbidity
10–15 years before their more affluent peers [12]. It challenges the usual care delivery,
which is frequently structured around pathways of care for single diseases [13,14]. This
can generate a tension between applying single-condition guidelines to patients with mul-
timorbidity as security against uncertainty or penalty and potentially causing patients
harm [15,16]. People suffering from multiple health conditions are more likely to require
an increased number of healthcare processes, triggering the involvement of an increased
number of health professionals [13,14,17]. This increased complexity in the delivery of care
threatens coordination and continuity, thereby decreasing the likelihood of receiving care
that meets the appropriate standards for patient safety [14].
A previous systematic review of the relationship between multimorbidity and patient
safety incidents in primary care found that both mental–physical multimorbidity and
physical multimorbidity were associated with a higher risk for active safety incidents (such
as adverse drug events and medical complications), whereas mental–physical comorbidity
(mainly depression) was associated with an increased risk for both active safety incidents
and precursors of safety incidents (such as a lower quality of care, prescription errors and
medication nonadherence) [18]. In developed countries, approximately 30% of patients
aged 65 years or older are prescribed five or more drugs. Whereas many may benefit
from such polypharmacy [19], it comes with an increased risk of adverse events in older
people due to the physiological changes of aging that alter the pharmacokinetic and
pharmacodynamic responses to drugs [20]. In addition to polypharmacy, other important
sources of unsafe care among patients with multimorbidity are communication-related
incidents, e.g., incomplete or nontransfer of information across care boundaries and clinical
decision-making incidents that lead to the most serious patient harm outcomes.
However, multimorbidity might be associated with higher (rather than lower) levels
of patient safety if the intrinsic high-risk profile of these patients results in an increased
patient safety activation of either the patients or the health professionals involved or
both. The presence of synergistic combinations may also provide increased incentives for
both patients and professionals for adhering to the guidelines for recommended care [21].
Indeed, in some cases, multimorbidity has been associated with a lower risk for safety
failures (e.g., a trend was observed for physical multimorbidity to be associated with better
quality of care) [18].
The relationship between multimorbidity and patient safety outcomes in primary care
is complex, with high levels of variability, and is influenced by differences in how multimor-
bidity is measured [18]. Attempts to study the impact of multimorbidity are complicated
by the lack of consensus about how to measure the concept [13]. Related constructs, such
as comorbidity (sets of conditions that coexist with a predefined index condition, further
classified as concordant and discordant based on the pathophysiology [22,23]; morbidity
burden (total burden of physiological dysfunction, which is affected both by the number
and the severity of conditions [9,24]) and clinical complexity (which acknowledges that the
complexity of care provision for any individual is influenced not only by health-related
characteristics but, also, by the socioeconomic, cultural, environmental and patient be-
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haviour characteristics [9,25]) are often used interchangeably [26]. Studies simultaneously
using and comparing the multiple approaches to measure multimorbidity are very much
needed to shed light on the mechanisms by which multimorbidity affects patient safety
and to identify groups of multimorbid patients at higher risk of safety events.
The aim of this study was to examine the complex relationships between patient-
reported patient safety outcomes and multimorbidity as conceptualized and measured
using the constructs of multimorbidity and polypharmacy, comorbidity, morbidity burden
and patient complexity and the pathways by which the multimorbidity constructs may be
associated with patient-reported patient safety in primary care.
2. Materials and Methods
2.1. Design
This is a cross-sectional study combining baseline data from the SinergiAPS phase II
and phase III trials [27]. The SinergiAPS project aims to develop and evaluate the effec-
tiveness of an intervention to improve patient safety in PHC centres by providing them
with patient feedback obtained through the administration of a standardized self-reports
of patient safety. Details of the phase II study are available elsewhere. In brief, the phase II
study consisted in a 3-month, uncontrolled, pre-post-study, including 10 primary health-
care (PHC) centres in Mallorca, Spain. Baseline data collection took place between October
and November 2018. In each PHC centre, all patients in the waiting room were consecu-
tively approached by a research assistant and invited to complete the Spanish version of
the Patient Reported Experiences and Outcomes of Safety in Primary Care (PREOS-PC)
questionnaire to report on their perceptions, experiences and outcomes in relation to the
safety of the healthcare received from their PHC centre over the previous 12 months. So-
ciodemographic and clinical information was also collected. All patients having visited
their PHC centre at least once during the previous 12 months were considered eligible to
complete the questionnaire. Patients aged <18 were eligible only if they were accompanied
by a carer or family member aged 18 or more willing to complete the questionnaire on their
behalf. Questionnaires were primarily self-administered using table computers. However,
paper versions of the questionnaire were also available upon request. Patients were also
given the opportunity of having the questionnaire administered by the researchers in situ.
We aimed to collect 50 questionnaires per centre. Questionnaire completion time was, on
average, 15 min. The phase III consisted in a 12-month, two-arm, two-level cluster random-
ized controlled trial, which is currently ongoing. It involves 59 PHC centres in Mallorca
(30 centres) and Catalonia (29 centres) that were selected to ensure variations in terms of
the list size, rurality and deprivation. Baseline data collection took place between June 2019
and January 2020 and involved the administration of 75 patient questionnaires per centre
(4425 questionnaires in total), following the same methodology previously described for
the phase II trial.
2.2. Multimorbidity and Related Constructs
We enhanced the proposal of Valderas et al. [9], which distinguished four key comor-
bidity constructs: multimorbidity, comorbidity, morbidity burden and patient complexity,
with the addition of polypharmacy (Figure 1).
1. Multimorbidity and polypharmacy. We measured multimorbidity as the total number
of self-reported long-term conditions for each respondent [28] (see below for the full
list). Previous studies measuring self-reported multimorbidity support the validity
of the self-reported approach [28–31]. Polypharmacy estimates were based on the
self-reported number of prescription drugs.
2. Comorbidity discordance. We classified pairs of conditions as concordant or dis-
cordant based on their pathophysiology. Concordant comorbidity was defined as a
set of conditions that are part of a shared pathophysiological pathway and thereby
more likely to share the same management and are more likely to be the focus of
the same disease management plan (e.g., hypertension and diabetes) [22,23]. Dis-
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cordant comorbidity was defined as sets of diseases that are “not directly related
in either pathogenesis or management and do not share an underlying predispos-
ing factor” (e.g., hypertension and osteoporosis). We hence classified as concordant
comorbidities the following sets of conditions: cardiovascular (which included “hy-
pertension”, “hypercholesterolemia”, “type 2 diabetes”, “long-term heart problem”
and “blood circulation problems”); mental health (“depression” and “other mental
health problems”) and musculoskeletal (“arthrosis and rheumatic problems” and
“osteoporosis”). The rest of the conditions, including “asthma or bronchitis or em-
physema”, “allergy”, “migraine or headaches”, “prostate-related problems”, “peptic
or gastric ulcer”, “inguinal hernia” and “menstruation-related problems”, were not
considered to be concordant with any other according to their pathophysiology. All
patients with more than one condition were thus classified in terms of increasing the
levels of comorbidity discordance as having (mutually exclusive, lowest-to-highest
discordance): (1) fully concordant multimorbidity (100% of the conditions classified as
concordant) or (2) predominantly concordant multimorbidity (at least one discordant
condition and >50% of the conditions classified as concordant), predominantly discor-
dant multimorbidity (at least one discordant condition and ≤50% of the conditions
classified as concordant) and totally discordant multimorbidity (100% of conditions
mutually discordant).
3. Morbidity burden. We developed an index of morbidity burdens based on the previ-
ous constructs (multimorbidity (number of conditions), polypharmacy (number of
medications and comorbidity discordance), and self-reported health status and age
(see details in Statistical Analysis).
4. Patient complexity. Finally, we constructed an index of patient complexity based on
the variables included in the development of the morbidity burden and included
the educational attainment, occupational status and country of origin (see details in
Statistical Analysis).
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Figure 1. Multimorbidity and related constructs.
2.3. Patient Safety
Patient safety was measured with the Patient Reported Experiences and Outcomes
of Safety in Primary Care (PREOS-PC) questionnaire [32]. PREOS-PC invites patients to
report on their perceptions and experiences concerning the safety of healthcare in their
practice over the past 12 months. In this study, we used the validated PREOS-PC 27 items
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Spanish version, which covers five main domains: practice activation (what does the
practice do to create a safe environment and to ensure safety). patient activation (how
pro-active are patients in ensuring safer healthcare), experiences of patient safety events
(errors). outcomes of patient safety (harm) and patients’ overall perception of safety (how
safe do patients think the practice is) [33].
Scale scores were calculated as the percentage of the maximum score achievable on
all items, with scores ranging from 0 to 100 (higher scores correspond to higher levels of
patient safety). For multi-item scales, a scale score was derived using the available items
without any imputation, except when more than 50% of the items were missing (scale
scored as missing). We developed an overall score of Patient Safety based on PREOS-PC
scales scores using a latent class analysis (see Statistical Analysis for details).
Further details on the conceptual framework and the development process, validation
and psychometric properties of the self-reported measures PREOS-PC survey are available
elsewhere [32–34].
2.4. Statistical Analysis
An assessment of model identification was made using the two-step rule [35]. First, we
used separate confirmatory factory analyses to develop the latent variables corresponding
to the domains “patient safety”, “morbidity burden” and “patient complexity” based on
the set of predefined observed variables previously described (see above). The suitability
of the allocation of each indicator to its corresponding domain was examined based on
their correlations and the loadings after a confirmatory factor analysis. We also estimated a
goodness of fit for the three models through estimation of the Standardized Root Mean
Squared Residual (SRMR) [36], Comparative Fit Index [37], Root Mean Square Error of
Approximation (RMSEA) and equation-level goodness of fit.
The association between the multimorbidity measures, number of visits and patient
safety was initially examined using separate bivariate and adjusted lineal regression mod-
els for each multimorbidity construct as the sole independent variable and the patient
safety latent variable as the dependent variable. We then constructed generalized structural
equation models (GSEM) [38,39]. GSEM allows to evaluate simultaneous relationships
among variables and is also useful to assess models with categorical variables and unob-
servable latent variables, since a GSEM structure links are latent and its measurements
variable. We used separate GSEM models for each of the multimorbidity and related
constructs. For the model on comorbidity, discordance estimates were calculated using the
completely concordant comorbidity group as the reference group. A statistical analysis
comprised the estimation of nonstandardized coefficients and 95% CI. Akaike’s information
criterion (AIC), which provides a trade between the goodness of fit and model simplicity,
was calculated for all GSEM models to facilitate a comparison and identification of the
best-performing model [40,41]. Given the exploratory, rather than confirmatory, nature
of our analysis, it was deemed a more suitable than the alternative Bayesian information
criterion [42]. All analyses were stratified by gender, and all regression and GSEM analyses
were adjusted by age, educational attainment and self-reported health status (except in
those cases where these potentially confounding variables were already used for the con-
struction of our multimorbidity latent measures). We were not able to use multilevel GSEM
because of the computational limitations. We therefore conducted sensitivity analyses
using multilevel regression models to adjust for clustering effects (as our Patient Safety
measure was likely to cluster among practices).
We hypothesized that multimorbidity constructs would be associated with patient
safety both via a direct and indirect pathway (Figure 2). Whereas, through the direct path-
way, we hypothesized a direct association between higher levels of multimorbidity and
worse patient safety; through the indirect pathway, we hypothesized that this association
would be mediated by the intensity of interactions with General Practice (i.e., higher multi-
morbidity directly associated with a higher number of visits and a higher number of visits
associated with worse patient safety). Increased number visits may both offer increased
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opportunities to addressing patient safety issues and, also, to increase the potential for
additional patient safety issues to arise. We did not make any a priori hypothesis as to what
of these potential mechanisms would be a larger impact on the net effect in the indirect
pathway. We hypothesized an inverse association between multimorbidity constructs and
patient safety via a direct pathway (higher levels of multimorbidity and related constructs
associated with higher levels of health care use and the latter associated with lower levels
of patient safety).
Questionnaires with missing data were excluded from the analyses. We used Stata
v15.1 and applied an α level of 5% throughout.
3. Results
Of the 6393 patients invited, 5010 accepted to complete the questionnaire (response
rate = 78.4%). After excluding 228 questionnaires with incomplete data, the baseline data
were available for 4782 adult patients from 69 primary care centres (Table 1). About two-
thirds of respondents were women, mean age was 52, half of them were working and a
third were retired. Almost half (44%) had visited their primary healthcare centres more
than five times during the last 12 months, and almost 80% had been registered at their
centre for more than five years. The population was broadly similar to that of other PHC
centres in the region. There were small but statistically significant differences between
women and men in terms of age, health status, educational and occupational status and
migration status (p < 0.05).
Table 1. Sociodemographic and clinical characteristics of the participants.
Women
(n = 3059; 64%)
Men
(n = 1723; 36%)
Total
(n = 4782)
Age
Mean (SD) 51.12 (18) 54.06 (19) 52.1 (19)
<18 56 (2%) 60 (3%) 116 (2%)
18–29 346 (11%) 160 (9%) 506 (11%)
30–44 747 (24%) 315 (18%) 1062 (22%)
45–64 1097 (36%) 581 (34%) 1678 (35%)
≥65 811 (27%) 607 (35%) 1418 (30%)
Educational level
University studies 597 (19%) 244 (14%) 835 (16%)
Other qualifications 1744 (57%) 1075 (62%) 2816 (59%)
No qualifications 724 (24%) 404 (23%) 1128 (24%)
Country of origin
Spain 2618 (86%) 1546 (90%) 4164 (87%)
Other country (European Union) 122 (4%) 56 (3%) 178 (4%)
Other country (Non-European Union) 319 (10%) 121 (7%) 440 (9%)
Occupational status
Working 1532 (50%) 804 (47%) 2336 (49%)
Unemployed 342 (11%) 87 (5%) 429 (9%)
Retired 862 (28%) 710 (41%) 1572 (33%)
Other (student, volunteering, etc.) 323 (11%) 122 (7%) 445 (9%)
Visits to PHC centre in the previous 12 months
1–5 1672 (55%) 993 (58%) 2665 (56%)
6–10 767 (25%) 388 (23%) 1155 (24%)
11–20 395 (13%) 230 (13%) 625 (13%)
>20 225 (7%) 112 (7%) 337 (7%)
Health status
Very good 366 (12%) 237 (14%) 603 (13%)
Good 1420 (46%) 891 (52%) 2311 (48%)
Fair 999 (33%) 472 (27%) 1471 (31%)
Bad 208 (7%) 96 (6%) 304 (6%)
Very bad 66 (2%) 27 (2%) 93 (2%)
Number of long-term conditions
Mean (SD; range) 2.20 (2.17; 0–16) 2.13 (1.95; 0–10) 2.17 (2.09; 0–16)
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Table 1. Cont.
Women
(n = 3059; 64%)
Men
(n = 1723; 36%)
Total
(n = 4782)
0 816 (27%) 441 (26%) 1257 (26%)
1 628 (21%) 331 (19%) 959 (20%)
2 to 3 865 (28%) 638 (37%) 1433 (30%)
>3 750 (25%) 383 (22%) 1131 (24%)
Long-term conditions
Hypertension 815 (27%) 611 (35%) 1426 (30%)
Hypercholesterolemia 684 (22%) 510 (30%) 1195 (25%)
Diabetes 309 (10%) 333 (19%) 642 (13%)
Asthma or bronchitis or emphysema 322 (11%) 178 (10%) 500 (10%)
Long-term heart problem 250 (8%) 284 (16%) 534 (11%)
Stomach ulcer 134 (4%) 58 (3%) 192 (4%)
Allergy 597 (20%) 244 (14%) 841 (18%)
Depression 523 (17%) 151 (9%) 674 (14%)
Other mental health problems 187 (6%) 91 (5%) 278 (6%)
Migraine/headaches 578 (19%) 107 (6%) 685 (14%)
Blood circulation problems 587 (19%) 219 (13%) 806 (17%)
Hernia 274 (9%) 220 (13%) 494 (10%)
Arthrosis and rheumatic problems 921 (30%) 349 (20%) 1270 (27%)
Osteoporosis 305 (10%) 25 (1%) 330 (7%)
Menstruation-related problems 232 (8%) - 232 (5%)
Prostate-related problems - 287 (17%) 287 (6%)
Number of medications
Mean (SD; range) 2.25 (2.94; 0–30) 2.61 (3.15; 0–27) 2.38 (3.02; 0–30)
0 1129 (38%) 560 (33%) 1689 (36%)
1 472 (16%) 253 (15%) 725 (16%)
2–4 1038 (35%) 607 (36%) 1645 (35%)
5–10 282 (9%) 216 (13%) 498 (11%)
>10 67 (2%) 40 (2%) 107 (2%)
The most prevalent chronic conditions for both men and women were hypertension,
arthrosis and rheumatic problems and hypercholesterolemia. Women reported more
frequently than men osteoporosis, migraines, depression and arthrosis and rheumatic
Problems, and about 8% of them reported period-related problems. Men reported more
frequently diabetes and heart problems, and 17% reported prostate-related problems.
3.1. Multimorbidity and Related Constructs
More than half of the women (53%) presented with multiple long-term conditions, with
an average of 2.2 conditions (men: 55%; 2.1 conditions; both comparisons nonsignificant
(n.s.)). Approximately half of the women (48%) were taking multiple medications, with
an average of 2.3 medications (men: 53% (n.s.); 2.6 (p < 0.01)). A small proportion of both
women and men reported taking more than 10 medications (2%).
Of the 2216 patients with more than one condition, 346 (13%) patients were classi-
fied as having fully concordant multimorbidity, 283 (11%) as predominantly concordant
multimorbidity, 1291 (50%) as having predominantly discordant multimorbidity and 646
(25%) as totally discordant multimorbidity. There were significant differences between
men and women (p < 0.01), with four out of five women (vs. two out three men) having
predominantly or completely discordant conditions and one out of 10 women (vs. one out
five men) having completely concordant conditions.
3.1.1. Morbidity Burden
Loadings for the latent variable “morbidity burden” (Appendix A, Table A1) ranged
from 0.38 to 0.98, whereas the correlations ranged from 0.38 to 0.99 (all statistically signifi-
cant). The Standardized Root Mean Square Residual (0.04) and Coefficient of Determination
(0.97) suggested an adequate model fit for the latent variable “morbidity burden”.
J. Clin. Med. 2021, 10, 1782 8 of 17
3.1.2. Patient Complexity
Loadings for the latent variable “patient complexity” (Appendix A, Table A2) ranged
from 0.12 to 0.97, whereas correlations ranged from −0.24 to 0.99 (all statistically significant).
The Standardized Root Mean Square Residual (0.06) and Coefficient of Determination (0.96)
suggested an adequate model fit.
3.2. Patient Safety
Mean scores for the PREOS-PC scales were high (>80/100), indicating high levels of
patient safety, for all the scales except for the scale patient activation (Table 2). No clinically
relevant differences were observed between men and women in any of the scale scores.
Table 2. Patient-reported patient safety with the PREOS-PC questionnaire.
Women Men Total
Mean (SD)
Score
Score Range
(Min–Max)
Mean (SD)
Score
Score Range
(Min–Max)
Mean (SD)
Score
Score Range
(Min–Max)
Patient activation 38.13 (36.93) 6.25–100 39.99 (37.85) 0–100 38.80 (37.27) 0–100
Team activation 79.81 (20.22) 6.25–100 84.01 (18.32) 18.75–100 81.32 (19.66) 6.25–100
Experiences of safety events 91.81 (13.33) 0–100 93.51 (12.25) 0–100 92.42 (12.98) 0–100
Harm (severity) 96.43 (11.86) 0–100 96.83 (11.75) 0–100 96.58 (11.81) 0–100
Harm (needs) 95.98 (12.61) 0–100 96.97 (10.99) 0–100 96.34 (12.06) 0–100
Overall rating of patient safety 83.51 (16.50) 0–100 84.82 (15.55) 0–100 83.98 (16.18) 0–100
In the confirmatory factor analysis, the latent variable was initially proposed based on
all the six PREOS-PC scales (Appendix A, Table A3). All scales loadings (>0.45) supported
the validity of the latent variable, with the exception of “Patient Activation” (loading =
0.32). After removing this scale, the loadings ranged from 0.46 to 0.79, suggesting that
all the scales explained a significant proportion of the variance of “Patient Safety”. All
the correlations between the individual PREOS-PC scales and the “Patient Safety” were
statistically significant (p < 0.001) and ranged from 0.55 to 0.93. The Standardized Root
Mean Square Residual (0.08) and Coefficient of Determination (0.76) suggested an adequate
model fit.
3.3. Association between Multimorbidity and Related Constructs and Patient Safety
3.3.1. Multimorbidity
In the bivariate lineal regression analysis, the number of conditions was associated
in women with lower patient safety, as predicted, but with higher patient safety in men
(Online Supplementary Material). The multivariate multilevel lineal regression confirmed
the results for women, while the results for men were not significant.
In GSEM (Figure 2a and Table 3), a higher number of conditions in women was
associated with worse patient safety through the direct pathway, whereas no statistically
significant associations were found through the indirect pathway (i.e., the association
between number of conditions and patient safety was not mediated by number of visits,
because the number of visits was not associated with patient safety). For men, no significant
associations were observed via the direct or indirect pathways.
3.3.2. Polypharmacy
In both the bivariate and the multivariate multilevel lineal regression analyses, the
number of medications was not associated with patient safety among women, while
(against our hypotheses) a higher number of medications was associated with higher levels
of patient safety for men.
The GSEM (Figure 2b) confirmed both the absence of association for women via either
pathway and the association with better (rather than worse) patient safety via the direct
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pathway for men. A simultaneous association with worse patient safety (consistent with a
priori hypotheses) was also observed for men.
3.3.3. Comorbidity Discordance
In the bivariate lineal regression analysis, a higher level of discordance was associated
with worse patient safety in both women and men, but the associations were rendered not
significant in the multivariate multilevel lineal regression analysis.
For women, however, statistically significant associations between patient safety
and two of the comorbidity discordance categories (“predominantly concordant” and
“predominantly discordant”) were observed in the GSEM analysis via the direct pathways,
whereas no significant associations were observed via the indirect pathways (number of
visits not associated with patient safety). For men, GSEM confirmed a lack of association
via either pathway (Figure 2c).
3.3.4. Morbidity Burden
In both the bivariate and the multivariate multilevel lineal regression analyses, a higher
morbidity burden was associated with a lower patient safety in women and, contrary to
our expectations, with a higher level of patient safety in men.
In the GSEM analysis (Figure 2d), a higher morbidity burden was associated in women
with lower patient safety via both pathways and for men via the direct pathway. At the
same time, the inverse association was observed for men via the direct pathway, against
the a priori hypotheses and consistent with the observations for a polypharmacy.
3.3.5. Patient Complexity
In both the bivariate and the multivariate multilevel lineal regression analyses, in
men, a higher patient complexity was associated with a higher patient safety, while no
significant association was observed in women.
In the GSEM analysis (Figure 2e), an association between higher patient complexity
and lower patient safety was observed both for men and women via the indirect pathway
(as, in both cases, a higher clinical complexity was associated with an increased number
of visits, which, in turn, was associated with lower patient safety). For men, a higher
patient complexity was directly associated with better patient safety (against our a priori
hypotheses), whereas, for women, no significant association was observed between patient
complexity and patient safety via the direct pathway.
For women, a consistent association between the lower levels of patient safety and
higher levels of the multimorbidity (Figure 2a), discordant comorbidity (Figure 2c), mor-
bidity burden (Figure 2d) and clinical complexity (Figure 2e) was observed via either the
direct pathway, the indirect pathway (i.e., mediated by number of visits during the last
12 months) or both. For men, an association between lower patient safety and higher
levels of polypharmacy (Figure 2b), morbidity burden (Figure 2d) and clinical complexity
(Figure 2e) was observed only via the indirect pathway. However, unexpected associations
between higher patient safety and higher levels polypharmacy, morbidity burden and
clinical complexity were observed via the direct pathways.
3.3.6. Comparison across Models
The least parsimonious models were the models including the latent variables mor-
bidity burden and patient complexity¸ which included the highest number of variables
(Table 3). Among those with a directly measured variable, the comorbidity discordance
model was the most parsimonious. The AIC was larger for women than for men, suggesting
a better fit of the models for men.
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Table 3. Associations between the different measures of multimorbidity, patient safety and number of visits by sex in the
final generalized structural equation models *.
Women (β (95% CI)) Men (β (95% CI))
Indirect Pathway DirectPathway AIC Indirect Pathway
Direct
Pathway AIC
MM to
Visits Visits to PS MM to PS
MM to
Visits Visits to PS MM to PS
Number of
conditions }
0.15 (0.13 to
0.16) *
−0.25 (−0.24
to 0.74)
−0.83 (−1.08
to −0.57) * 129,086.9
0.16 (0.14 to
0.18) *
−0.09 (−0.65
to 0.47)
0.15 (−0.17
to 0.48) 71,554.63
Number of
medications }
0.12 (0.10 to
0.13) *
−0.22 (−0.73
to 0.29)
−0.09 (−0.28
to 0.10) 126,845.7
0.12 (0.11 to
0.14) *
−0.54 (−1.08
to −0.01) *
0.21 (0.03 to
0.39) * 69,863.42
Comorbidity
discordance } 69,106.07 39,370.94
Completely
concordant (ref.) - - - -
Predominantly
concordant
0.32 (0.10 to
0.54) *
−3.67 (−6.44
to −0.90) *
0.30 (0.09 to
0.52) *
0.18 (−1.78
to 2.15)
Predominantly
discordant
0.02 (−0.15
to 0.20)
−3.34 (−5.53
to −1.16) *
0.19 (0.03 to
0.35) *
−0.43 (−1.88
to 1.03)
Completely
discordant
−0.30
(−0.49 to
−0.12) *
−0.18 (−0.46
to 0.82)
−0.89 (−3.27
to 1.49)
−0.18
(−0.36 to
−0.01) *
−0.12 (−0.69
to 0.46)
−0.52 (−2.20
to 1.16)
Morbidity burden ¶ 0.34 (0.30 to0.37) *
−0.88 (−1.36
to −0.40) *
−0.67 (−1.17
to −0.18) * 191,973
0.36 (0.31 to
0.41) *
−0.96 (−1.42
to −0.51) *
0.79 (0.32 to
1.26) * 107,340
Patient Complexity † 0.36 (0.32 to0.40) *
−0.79 (−1.27
to −0.31) *
−0.11 (−0.61
to 0.39) 211,882.2
0.38 (0.33 to
0.43) *
−1.00 (−1.46
to −0.53) *
0.87 (0.38 to
1.36) * 117,935
β: unstandardized coefficients, CI: confidence interval, AIC: Akaike information criterion, MM: multimorbidity, PS: patient safety, Visits:
number of visits to the primary care centre during the last 12 months and ref: reference category. }adjusted by age, educational attainment
and self-reported health status. * Statistically significant associations (p < 0.05) are noted with an asterisk (*).¶ adjusted by educational
attainment (age and self-reported health status already included in the development of the “Morbidity burden” latent variable). † not
adjusted (age, educational attainment and self-reported health status already included in the development of the “Patient Complexity”
latent variable). Dark grey cells: path consistent with the direction of a priori hypotheses, white cells: path not consistent or opposed to the
a priori hypotheses and pale grey cells: path in the opposite direction of the a priori hypotheses.
4. Discussion
In this study, we examined the association between patient-reported patient safety
and a range of comorbidity measures derived from the literature. For women, and as
hypothesized, a consistent association between higher levels of the constructs and lower
levels of patient safety was observed indirectly via an increased number of visits (patient
complexity), directly (number of conditions and comorbidity discordance) or both (mor-
bidity burden). While the findings for men were consistent with these observations for
the indirect pathway (polypharmacy, morbidity burden and patient complexity), we also
found an unexpected and simultaneous yet remarkably consistent direct association with
better (rather than worse) patient safety for these constructs.
4.1. Discussion of Main Findings and Comparison with the Previous Literature
The reasons for the observed gender difference are not fully clear. Although there did
not seem to be any differences in number of conditions, there were gender differences in the
proportion of each condition—in particular, the most frequent conditions among women
were more frequently mutually discordant than for men (just 29% of those conditions with
a prevalence higher than 15% among women were concordant while the proportion was
67% for men (all cardiometabolic)). The differential associations between the raw number
of conditions (and medications) and patient safety could be attributed to differential
proportions of comorbidity discordance due to differential epidemiological profiles linked
to gender. However, this would also explain no differential effect being observed for the
GSEM for comorbidity discordance. This would also, at least in part, explain that the
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differential effect was also observed for the morbidity burden and clinical complexity,
which included both the number of conditions and medications as well as comorbidity
discordance in their construction, as well as other variables. However, the effect did not
seem to be attenuated by the inclusion of a larger number of additional variables in the
clinical complexity index (five) compared to the morbidity index (two).
It is also conceivable that the differences may be related to different frequencies in
the presence of other conditions not included in the self-report of our study and, also, by
different patterns of association (clusters) with implications for management that may not
be fully captured by our approach to measuring comorbidity discordance (we note that
we were only able to define and measure concordance a priori based on conditions, rather
than a posteriori, based on actual concordance between medications). They could also be
an expression of larger gender healthcare inequalities that have already been established in
a large number of other areas of healthcare. There is no reason to presume that these are
necessarily mutually exclusive explanations.
The “comorbidity discordance” model was the most parsimonious for both women
and men. Since this model was one of the three not including a latent variable as a multimor-
bidity construct, it would suggest that models for “multimorbidity” and “polypharmacy”
would be underfit, whereas the more complex models with the latent variables “morbidity
burden” and “patient complexity” (which included all the previous constructs) would
be overfit.
A previous comprehensive systematic review identified that different types of mul-
timorbidities resulted in different risks of adverse patient safety outcomes. In particular,
a physical–mental comorbidity was associated with an increased risk of both active and
precursors of safety incidents whereas physical comorbidity was associated only with a
smaller risk active safety incidents [18]. Our findings would be consistent with these obser-
vations that comorbidity discordance (physical–mental comorbidity being an example) is
associated with worse levels of patient safety. No stratification was done for gender.
A previous study with 1190 patients registered in 45 practices did not show any
association between multimorbidity and polypharmacy and selected PREOS-PC scores
in a regression model with patient and practice activation as independent variables and
adjusted for a range of clinical and sociodemographic characteristics, but not gender, as
it was not statistically significantly associated with the dependent variables in bivariate
analyses [43].
Similarly, a recent study aiming to identify high-need patients with multimorbidities
concluded that people who frequently contact the general practice use general practice
out-of-office services or have unplanned admissions that are largely distinct high-need
subgroups but did identify gender-specific differences [44].
4.2. Strengths and Limitations
This study has several strengths. The population included is largely representative
of the broad primary care reference population, patient safety was measured using a
validated tool and appropriate analytical approaches were implemented to model the
relevant associations. A number of limitations also need to be considered. First, its cross-
sectional design limits the inferences about causality. We cannot rule out that, in some cases,
the safety events experienced could have led to increased multimorbidity or polypharmacy.
There is good evidence that safety incidents are relatively common in the primary care
setting and are of significant importance when considered as a whole, but most of them do
not result in serious harm [3]. This was also the case in our study, in which the severity
of harm reported by the study participants was low (as evidenced by the high scores on
the harm scales; Table 2). Therefore, this potential reversed causality is unlikely to have
played a major role in this study. Future studies should consider using a longitudinal
design to overcome this limitation. Second, this is a secondary analysis of the baseline
data of two trials. The sample size was therefore limited and may have contributed to
a lack of convergence of the multilevel GSEM analyses. Further, the available data on
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self-reported morbidity were also limited based on the protocol for the original study. The
inclusion of additional diseases in the modelling would have allowed to obtain a more
comprehensive description of the morbidity status of the individual. Although this is likely
to have had the biggest impact on the multimorbidity and discordant comorbidity and, to
some degree, on the latent indexes that we constructed based on them, it must be noted
that these indexes relied on additional variables, thereby attenuating the impact of either
the multimorbidity -or discordant multimorbidity on the latent variables. Thirdly, the
multimorbidity latent variables morbidity burden and patient complexity were developed
using variables that the models for multimorbidity, polypharmacy and discordance were
adjusted for. Although it would not have been appropriate to adjust for these variables in
the multimorbidity latent variables model, it may be argued that the resulting models may
benefit from further adjustment.
4.3. Implications for Research, Practice, Policy
Our study suggests that it is feasible to operationalize a range of different multimorbid-
ity constructs presented in the literature. Further research implementing both similar and
alternative operationalisations—in particular, including the locus of control and continuity
of care as additional variables in the construction of the clinical complexity index [45,46]—
are necessary for further validation of the approach and for exploring the associations
in other contexts. The comorbidity discordance appears as a promising instrument in
establishing the mechanisms by which multimorbidity is associated with worse healthcare
outcomes [47]. Reanalysis of the existing data with a comorbidity discordant approach
may provide an efficient approach to shedding light on the mechanisms by which previous
associations with more blunt approaches (count of conditions) have been reported [48].
Further research is needed to replicate the observed gender-specific differences and,
if confirmed, to elucidate their nature and operating mechanisms.
Our latent class analysis of PREOS-PC present with an opportunity for the considera-
tion of the overall scores that may facilitate the interpretation of patient feedback and its
communication to health professionals.
For women, particularly those with discordant comorbidity, the observed detrimental
effects of multimorbidity and related constructs on patient safety make it necessary that
efforts in the development, implementation and evaluation of the safe process of care
prioritize these vulnerable patients. In the absence of standards of care based on robust
evidence for people with multimorbidities [16], in particular, patient safety appears as a
key focus in the provision of care.
5. Conclusions
In this study, we observed that, in women, an increased number of conditions, number
of medications, comorbidity discordance, morbidity burden and patient complexity are
associated with worse patient safety (either through direct associations, through indirect
associations mediated by number of visits or both). In men, the pattern of associations
is more complex: although increased polypharmacy, morbidity burden and patient com-
plexity are associated with worse safety through an indirect pathway (mediated by an
increased number of visits), at the same time, these three multimorbidity constructs are
unexpectedly associated with better safety through a direct pathway.
Women with discordant multimorbidities appear as a relevant target group for the
development of interventions aimed at improving patient safety in primary care. Fur-
ther research—particularly, qualitative research—is needed for clarifying the complex
associations among men.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/jcm10081782/s1: Online Appendix 1. Bivariate and adjusted associations between the patient
safety, number of visits and multimorbidity constructs by gender.
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Appendix A. Description of the Latent Variables
Table A1. Description of the morbidity burden latent variables: pairwise correlations between the
proposed indicators and the latent variables and loadings in the confirmatory factor analysis.
Morbidity burden Pairwise Correlations Confirmatory Factor AnalysisLoadings (95% CI)
Women Men Women Men
Number of conditions 0.99 * 0.99 * 0.96 (0.95 to 0.97) 0.98 (0.97 to 0.99)
Discordance of conditions 0.92 * 0.89 * 0.89 (0.88 to 0.90) 0.88 (0.86 to 0.89)
Number of medications 0.66 * 0.68 * 0.64 (0.62 to 0.66) 0.67 (0.64 to 0.70)
Age 0.58 * 0.59 * 0.57 (0.54 to 0.60) 0.58 (0.55 to 0.62)
Self-reported health status a 0.47 * 0.38 * 0.46 (0.43 to 0.49) 0.38 (0.34 to 0.42)
* Statistically significant correlations (p < 0.001). a Higher scores indicative of worse self-reported health status.
Table A2. Description of the patient complexity latent variables: pairwise correlations between
each of the selected indicators for patient complexity and the patient complexity latent variable and
loadings in the confirmatory factor analysis.
Patient Complexity Pairwise Correlations Confirmatory Factor Analysis(Loadings (95% CI))
Women Men Women Men
Number of conditions 0.98 * 0.99 * 0.96 (0.95 to 0.96) 0.97 (0.97 to 0.98)
Concordance of the
conditions 0.92 * 0.90 * 0.90 (0.89 to 0.90) 0.88 (0.87 to 0.89)
Number of medications 0.67 * 0.69 * 0.65 (0.63 to 0.67) 0.67 (0.65 to 0.70)
Age 0.59 * 0.60 * 0.58 (0.55 to 0.60) 0.59 (0.56 to 0.63)
Self-reported health status a 0.47 * 0.39 * 0.47 (0.44 to 0.50) 0.38 (0.34 to 0.42)
Educational attainment b −0.38 * −0.24 * 0.38 (0.33 to 0.40) 0.23 (0.18 to 0.28)
Occupational status c 0.26 * 0.33 * 0.25 (0.22 to 0.29) 0.33 (0.28 to 0.37)
Country of origin d −0.12 * −0.14 * 0.12 (0.08 to 0.16) 0.14 (0.09 to 0.18)
* Statistically significant correlations (p < 0.001). a Higher scores indicative of a worse self-reported health status,
b higher scores indicative of higher educational attainment, c higher scores indicative of a worse occupational
status and d higher scores indicative of belonging to a non-EU country.
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Table A3. Description of the patient safety latent variables: pairwise correlations between scales and
the latent variables and loadings in the confirmatory factor analysis.
Patient Safety Pairwise Correlations Confirmatory Factor AnalysisLoadings (95% CI)
Women Men Women Men
Team activation 0.60 * 0.55 * 0.52 (0.48 to 0.55) 0.46 (0.41 to 0.51)
Experiences of safety events 0.93 * 0.90 * 0.79 (0.76 to 0.84) 0.75 (0.70 to 0.81)
Harm-severity 0.56 * 0.59 * 0.48 (0.44 to 0.52) 0.50 (0.45 to 0.54)
Harm-needs 0.55 * 0.57 * 0.47 (0.43 to 0.51) 0.48 (0.43 to 0.53)
Overall rating of patient
safety 0.65 * 0.67 * 0.56 (0.52 to 0.60) 0.56 (0.51 to 0.61)
* Statistically significant correlations (p < 0.001).
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